Innova Captab
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Innova Captab Limited is poised for growth, driven by the successful ramp-up of its new multipurpose facility in Jammu and recent regulatory approvals that enhance its competitive position in international markets. Management's optimistic outlook, projecting over 20% revenue growth, is underpinned by an expanding product portfolio and increased customer engagement in both contract development and branded generics. However, execution risks related to facility integration and rising API prices due to geopolitical tensions present challenges. Vista's financial outlook reflects a moderation in revenue growth, with stable margins expected, aligning with the company's fair valuation. The anticipated expansion into new markets and product lines supports Vista's target price of approximately 1,150, with a modest expected upside. Industry dynamics, including the growing demand for contract manufacturing and the shift away from China, further bolster Innova's prospects. Over the next 12-24 months, key opportunities include successful facility ramp-ups and market expansion, while watchpoints include execution risks and potential regulatory pressures
Why We Like This Stock
- Successful ramp-up of the Jammu facility is expected to significantly enhance production capacity and revenue
- Regulatory approvals for key facilities position Innova Captab favorably for increased export opportunities
- Management's optimistic revenue growth projection of over 20% reflects strong demand and operational leverage
Things To Watch Out For
- Execution risks associated with the ramp-up of new facilities could impact revenue realization
- Rising API prices due to geopolitical conflicts may pressure margins despite a cost-plus pricing model
- Regulatory pressures from Schedule M implementation could affect compliance and operational efficiency
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,081 | 1,244 | 1,630 | 1,779 | 2,042 |
| Profit Before Tax (Cr.) | 128 | 171 | 188 | 205 | 235 |
| PBT Margin | 11.8% | 13.7% | 1153.4% | 11.5% | 11.5% |
| Net Profit (Cr.) | 100 | 144 | 163 | 177 | 204 |
| Earnings Per Share | 17.5 | 25.2 | 28.4 | 30.9 | 35.6 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors, stockists, and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.